Fauna Bio

Fauna Bio is an AI-driven drug discovery company that mines roughly 100 million years of evolved disease resistance in mammals to find new human therapies. Founded in 2018 in the San Francisco Bay Area, it combines comparative genomics, a proprietary animal biobank, and machine learning - through its Convergence and Fauna Brain platforms - to translate the biology of hibernators and other resilient species into drug targets for conditions like obesity, heart failure, neurodegeneration, and retinal disease. Its work has attracted a partnership with Eli Lilly worth up to $494 million.